S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
OTCMKTS:CDXI

Cardax Stock Forecast, Price & News

$0.89
-0.11 (-11.00 %)
(As of 12/6/2021 10:46 AM ET)
Add
Compare
Today's Range
$0.89
$0.89
50-Day Range
$0.25
$1.50
52-Week Range
$0.05
$6.00
Volume
200 shs
Average Volume
544 shs
Market Capitalization
$736,030.00
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.02
30 days | 90 days | 365 days | Advanced Chart
Receive CDXI News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardax and its competitors with MarketBeat's FREE daily newsletter.


Cardax logo

About Cardax

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The firm It focuses on astaxanthin, a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. Its product platform includes pharmaceutical candidates CDX-101 and CDX-301; and dietary supplements ZanthoSyn. The company was founded on February 7, 2014 and is headquartered in Honolulu, HI.

Headlines

Cardax (OTCMKTS:CDXI) Trading 44.4% Higher
November 26, 2021 |  americanbankingnews.com
Cardax Refocuses on ZanthoSyn® Consumer Health Business
August 31, 2021 |  finance.yahoo.com
Cardax Voluntarily Suspends SEC Reporting Obligations
August 12, 2021 |  finance.yahoo.com
Cardax Reports Q1 2021 Results
May 14, 2021 |  finance.yahoo.com
Cardax Reports 2020 Results
April 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CDXI
Employees
11
Year Founded
N/A

Sales & Book Value

Annual Sales
$540,000.00
Book Value
($13.02) per share

Profitability

Net Income
$-5.06 million
Net Margins
-1,082.47%
Pretax Margin
-1,082.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$736,030.00
Optionable
Not Optionable

Company Calendar

Today
12/08/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Cardax (OTCMKTS:CDXI) Frequently Asked Questions

What stocks does MarketBeat like better than Cardax?

Wall Street analysts have given Cardax a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Cardax's key executives?

Cardax's management team includes the following people:
  • David G. Watumull, President, Chief Executive Officer & Director
  • David M. Watumull, COO, Secretary & Assistant Treasurer
  • John B. Russell, Chief Financial Officer & Treasurer
  • Gilbert M. Rishton, Chief Science Officer
  • Timothy J. King, Vice President-Research

What is Cardax's stock symbol?

Cardax trades on the OTCMKTS under the ticker symbol "CDXI."

How do I buy shares of Cardax?

Shares of CDXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardax's stock price today?

One share of CDXI stock can currently be purchased for approximately $0.89.

How much money does Cardax make?

Cardax has a market capitalization of $736,030.00 and generates $540,000.00 in revenue each year. The company earns $-5.06 million in net income (profit) each year or ($7.07) on an earnings per share basis.

How many employees does Cardax have?

Cardax employs 11 workers across the globe.

What is Cardax's official website?

The official website for Cardax is www.cardaxpharma.com.

Where are Cardax's headquarters?

How can I contact Cardax?

Cardax's mailing address is 2800 WOODLAWN DRIVE SUITE 129, HONOLULU HI, 96822. The company can be reached via phone at (808) 457-1400 or via email at [email protected].


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.